DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

Ophthotec (NASDAQ: OPHT)

52.39 0.50 (0.96%)

Quote as of

company name or ticker

Recent Quotes

OPHT $52.39 0.96%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $51.98
Previous Close $51.89
Daily Range $51.88 - $52.78
52-Week Range $35.38 - $58.29
Market Cap $1.8B
P/E Ratio -24.83
Dividend (Yield) $0.00 (0.0%)
Volume 173,783
Average Daily Volume 238,559
Current FY EPS -$2.62



Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website:

News & Commentary Rss Feed

3 Little-Known Biotechs Working On Potential Blockbusters

These three biotechs have promising drugs in their pipelines that address billion dollar drug markets.

Commit To Buy Ophthotech Corp At $40, Earn 8.1% Annualized Using Options

Ophthotech's (OPHT) CEO David Guyer on Q1 2015 Results - Earnings Call Transcript

Will AVEO Pharmaceuticals (AVEO) Surprise This Earnings? - Analyst Blog

AVEO Upgraded to Strong Buy, Add to Your Portfolio - Analyst Blog

3 Little-Known Stocks I'm Glad I Bought

Ophthotech Corp, Portola Pharmaceuticals Inc., and Insys Therapeutics Inc., have been top performers this past year.

2 Tiny Biotechs That Could Have Blockbuster Opportunity

Got risk tolerance? Check out these two small cap biotechs with huge potential.

Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog

Ophthotech's (OPHT) CEO Dr. David Guyer on Q4 2014 Results - Earnings Call Transcript

Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog

See More OPHT News...